93 related articles for article (PubMed ID: 36095962)
1. Single-intraosseous simvastatin injection suppresses cancers via activating CD8
Yuan W; Ren X; Zhu J; Huang J; Zhang W; Zhang C; Guan Z; Wang H; Leng H; Song C
Biomed Pharmacother; 2022 Nov; 155():113665. PubMed ID: 36095962
[TBL] [Abstract][Full Text] [Related]
2. Tumor antigen-specific CD8
Lu X; Yang L; Yao D; Wu X; Li J; Liu X; Deng L; Huang C; Wang Y; Li D; Liu J
Cell Immunol; 2017 Mar; 313():43-51. PubMed ID: 28110884
[TBL] [Abstract][Full Text] [Related]
3. Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors.
Ngiow SF; von Scheidt B; Akiba H; Yagita H; Teng MW; Smyth MJ
Cancer Res; 2011 May; 71(10):3540-51. PubMed ID: 21430066
[TBL] [Abstract][Full Text] [Related]
4. Single-dose local intraosseous injection of simvastatin suppresses breast cancer with tumor vascular normalization.
Yuan W; Hai B; Ren X; Zhu J; Zhang C; Guan Z; Jia J; Wang H; Cao B; Song C
Transl Oncol; 2020 Dec; 13(12):100867. PubMed ID: 32950929
[TBL] [Abstract][Full Text] [Related]
5. PD-1+ Tim3+ tumor-infiltrating CD8 T cells sustain the potential for IFN-γ production, but lose cytotoxic activity in ovarian cancer.
Sawada M; Goto K; Morimoto-Okazawa A; Haruna M; Yamamoto K; Yamamoto Y; Nakagawa S; Hiramatsu K; Matsuzaki S; Kobayashi E; Kawashima A; Hirata M; Iwahori K; Kimura T; Ueda Y; Kimura T; Wada H
Int Immunol; 2020 May; 32(6):397-405. PubMed ID: 32009163
[TBL] [Abstract][Full Text] [Related]
6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
8. CXCR5
Jin Y; Lang C; Tang J; Geng J; Song HK; Sun Z; Wang J
Int Immunopharmacol; 2017 Dec; 53():42-48. PubMed ID: 29032029
[TBL] [Abstract][Full Text] [Related]
9. CD8
Tao J; Han D; Gao S; Zhang W; Yu H; Liu P; Fu R; Li L; Shao Z
J Cell Mol Med; 2020 Jan; 24(1):1046-1058. PubMed ID: 31756785
[TBL] [Abstract][Full Text] [Related]
10. Antigen spreading-induced CD8+T cells confer protection against the lethal challenge of wild-type malignant mesothelioma by eliminating myeloid-derived suppressor cells.
Yu Z; Tan Z; Lee BK; Tang J; Wu X; Cheung KW; Lo NT; Man K; Liu L; Chen Z
Oncotarget; 2015 Oct; 6(32):32426-38. PubMed ID: 26431275
[TBL] [Abstract][Full Text] [Related]
11. Effects of immune checkpoint blockade on antigen-specific CD8
Ogando-Rivas E; Castillo P; Jones N; Trivedi V; Drake J; Dechkovskaia A; Candelario KM; Yang C; Mitchell DA
Microbiol Immunol; 2022 May; 66(5):201-211. PubMed ID: 35150167
[TBL] [Abstract][Full Text] [Related]
12. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ.
Moran AE; Polesso F; Weinberg AD
J Immunol; 2016 Sep; 197(6):2509-21. PubMed ID: 27503208
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A; Virk Y; Corgnac S; Mami-Chouaib F
Front Immunol; 2018; 9():14. PubMed ID: 29403496
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
16. Tumor Endothelial Cell-Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway.
Taguchi K; Onoe T; Yoshida T; Yamashita Y; Tanaka Y; Ohdan H
Mol Cancer Res; 2020 Sep; 18(9):1427-1440. PubMed ID: 32527950
[TBL] [Abstract][Full Text] [Related]
17. Dual TGF-β and PD-1 blockade synergistically enhances MAGE-A3-specific CD8
Chen X; Wang L; Li P; Song M; Qin G; Gao Q; Zhang Z; Yue D; Wang D; Nan S; Qi Y; Li F; Yang L; Huang L; Zhang M; Zhang B; Gao Y; Zhang Y
Int J Cancer; 2018 Nov; 143(10):2561-2574. PubMed ID: 29981155
[TBL] [Abstract][Full Text] [Related]
18. PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii.
Splitt SD; Souza SP; Valentine KM; Castellanos BE; Curd AB; Hoyer KK; Jensen KDC
Infect Immun; 2018 Sep; 86(9):. PubMed ID: 29967089
[TBL] [Abstract][Full Text] [Related]
19. miR-149-3p reverses CD8
Zhang M; Gao D; Shi Y; Wang Y; Joshi R; Yu Q; Liu D; Alotaibi F; Zhang Y; Wang H; Li Q; Zhang ZX; Koropatnick J; Min W
Open Biol; 2019 Oct; 9(10):190061. PubMed ID: 31594465
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.
Fourcade J; Sun Z; Benallaoua M; Guillaume P; Luescher IF; Sander C; Kirkwood JM; Kuchroo V; Zarour HM
J Exp Med; 2010 Sep; 207(10):2175-86. PubMed ID: 20819923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
